Author: Editor

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer explains CAR-T treatment in hematological malignancies affecting clinicians and moving forward with the COVID-19 pandemic. Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that…

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer answers commong questions on CAR-T treatment in hematological malignancies and the toxicities used. Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that underlie disease…

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer discusses CAR-T treatment in hematological malignancies.   Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that underlie disease relapse, adverse effects and cost. This…

This quick tutorial shows in detail how to create an account on OncologyTube.com and how to upload a video. The account is free and you will be able to add oncology and cancer specific videos and share them with our robust health care professional network.

Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director, Experimental Therapeutics Cedars Sinai Foundation discusses the Multi-Modality Management of Melanoma in the Era of Immunotherapy This presentation is a part of the MOASC Oncology Summit Annual Educational Symposium This presentation was made possible by these companies: Abbvie Oncology Amag Pharmaceuticals AstraZeneca Bayer Oncology BeiGene Clovis Oncology Coherus BioSciences Daiichi-Sankyo Jazz Pharmaceuticals Merck Pfizer Oncology Puma Biotechnology Takeda Oncology Tempus Verastem Oncology Walgreens    

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia: how this affects clinicians and treatment. _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly…

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia: what is the significance of this? _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly…

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia. _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly doses of rituximab 375 mg /…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews addresses how the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer affects clinicians and treatment today. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and PFS were the…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews answers if this can be extended to the community on the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and…

Company completes CLIA Validation of DetermaIOâ„¢, previously the Insight Genetics IM Score Test, establishing the test as a reliable and robust assay for identifying patients likely to respond tocheckpoint inhibitor therapy Data presented at the SITC conference in 2019 suggested that DetermaIOâ„¢ outperforms PD-L1 testingand Tumor Mutational Burden (TMB) in predicting both responders and non-responders to checkpointinhibitors Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it had completed CLIA Validation for DetermaIOâ„¢, previously the Insight Genetics IM Score Test. The company…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews discusses the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and PFS were the prespecified coprimary endpoints. TTB, a composite…

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses the effects of cardiac toxicities in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. ____________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer answers common questions in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. Does this data reflect our everyday practice? ____________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses findings in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. ______________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Experience with COVID-19 in Wuhan, China shows up to half of patients present with a digestive symptom as chief complaint Digestive symptoms are common in COVID-19, occurring as the chief complaint in nearly half of patients presenting to hospital according to a new descriptive, cross-sectional multicenter study from China by investigators from the Wuhan Medical Treatment Expert Group for COVID-19 published today in The American Journal of Gastroenterology, the official publication of the American College of Gastroenterology. Most patients with COVID-19 present with typical respiratory symptoms and signs. However, early experience with the outbreak in Wuhan, China revealed that many patients…

Experts from Seattle Cancer Care Alliance share lessons learned from early experiences treating people with cancer during COVID-19 outbreak via free online article in JNCCN—Journal of the National Comprehensive Cancer Network Experts from the Seattle Cancer Care Alliance (SCCA)—a Member Institution of the National Comprehensive Cancer Network® (NCCN®)—are sharing insights and advice on how to continue providing optimal cancer care during the novel coronavirus (COVID-19) pandemic. SCCA includes the Fred Hutchinson Cancer Research Center and the University of Washington, which are located in the epicenter of the COVID-19 outbreak in the United States. The peer-reviewed article sharing best practices is available for free online-ahead-of-print via open access…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers if this will affect clinicians and treatment for progression-free survival for breast and kidney cancer may extend survival for head and neck cancer patients. ______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers what type of TP53 mutations benefited from this for a drug used for breast and kidney cancer may extend survival for head and neck cancer patients. _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers questions on immunotherapy for a drug used for breast and kidney cancer may extend survival for head and neck cancer patients. _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and the advantage continued…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO discusses a drug used for breast and kidney cancer may extend survival for head and neck cancer patients.  _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and the advantage continued for those with mutations…

 VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously untreated chronic lymphocytic leukemia (CLL)   – Approval is based on data from the Phase 3 CLL14 trial, which showed that patients treated with obinutuzumab plus one year of treatment with VENCLYXTO had superior progression-free survival (PFS) and higher rates of undetectable minimal residual disease compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil[1],[5]   NORTH CHICAGO, Ill., March 12, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC)…

Allison King, MD of Washington University School of Medicine @WUSTLmed answers the gender disparities in hematology research: how this will affect clinicians and treatment. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification…

Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the results on gender disparities in hematology research success. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification as a carer was…

Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the study on gender disparities in hematology research success. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification as a carer…

Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results: a possible impact on broader therapy. Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results: what is the mechanism and how does it work?  Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Tom Davis, MD @ThomasADavisMD of @GenoceaBio discusses the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results in Q2/Q3 2020. Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19 and new projects that are either oncologically oriented or immune regulatory. #cancer #covid19 #coronavirus #immune #cancer #biotherapies #treatment #covid19 #coronavirus _____________ Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year partnership to create new, fully human antibodies to treat and prevent various diseases including oncology and immunology. The collaboration will also use the H2L2 Harbor Mice ® platform to produce monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies may be…

Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19. #cancer #biotherapies #treatment #covid19 #coronavirus __________ Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year partnership to create new, fully human antibodies to treat and prevent various diseases including oncology and immunology. The collaboration will also use the H2L2 Harbor Mice ® platform to produce monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies may be used therapeutically for people exposed to the virus, or prophylactically for people at high risk…

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC affecting clinicians and treatment. #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC: how did the patients do? #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

JNJ-6372, a dual-targeting EGFR-MET bispecific antibody, is being investigated for adults with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion mutations The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[i] Currently, there are…

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC.  #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells: how does this affect clinicians today? _____________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The Mount Sinai team reports that modulation of metabolic…

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells, potentially opening a new approach for bone marrow transplant: what about human stem cells? _______________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The…

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell discusses a way to enhance the potency of blood-forming stem cells, potentially opening a new approach for bone marrow transplant. _______________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The Mount Sinai team reports that…

Mount Sinai researchers have discovered a way to enhance the potency of blood-forming stem cells, potentially opening the door to a new approach for bone marrow transplantation, according to a study being published on February 27 in Cell Stem Cell. The scarcity of blood-forming stem cells, known as hematopoietic stem cells (HSCs), severely limits bone marrow transplantation, which can cure many blood disorders and solid tumors. The Mount Sinai team reports that manipulation of metabolic activity around lysosomes, the storage and recycling centers within cells, can increase by more than 90-fold the potency of blood-forming stem cells in bone marrow transplantation.…

Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise. NEW YORK, NY, CAMBRIDGE, MA, ROTTERDAM, NL, and SUZHOU, CN - Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology. The collaboration will also utilize the H2L2 Harbour Mice® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies could be used therapeutically for people who…

The standard of care for small-cell lung cancer (SCLC) had been unchanged for over 20 years, with platinum-based chemotherapy being the treatment of choice for extensive-stage (ES) disease. However, in 2018, the approval of Bristol-Myers Squibb’s Opdivo (nivolumab) in the second-line setting marked the beginning of the immunotherapy era for ES-SCLC. Sakis Paliouras, Oncology and Hematology Analyst at GlobalData, comments: “The US Food and Drug Administration (FDA) approved Genentech’s Tecentriq (atezolizumab) in combination with chemotherapy as a first-line treatment for ES-SCLC based on a 30% reduction in risk of death observed in the Phase III IMpower133 trial. This approval established…

Neal Shore, MD of Carolina Urologic Research Center @AtlanticUrology explains the randomized phase II study of sipuleucel-T with or without radium-223: how this affects clinicians and treatment today. ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio will be presented at the 2020 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers…

Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223 in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). Commonly asked questions: would this be a good way for patients with mildly symptomatic predominately with bone lesions to combine therapy? ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32,…

Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223 in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). ______________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio…

Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO and PBO in healthy volunteers:how developed is the MRI technology? ______________   New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving…

Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO and PBO in healthy volunteers:how developed is the MRI technology? ______________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology…

Neal Shore, MD of Carolina Urologic Research Center explains cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide compared to darolutamide and placebo in healthy volunteers. ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio…

– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients – – Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy Compared to Crizotinib –   Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not…

NCCN celebrates 25th anniversary year; shares updates from oncology experts on leading-edge cancer management practices during NCCN 2020 Annual Conference in Orlando. #NCCN2020 — Cancer care providers will gather in Orlando on March 20-22 for the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference: Celebrating 25 Years of NCCN. The three-day, in-person conference features more than 30 educational sessions on state-of-the-art practices in cancer care. Leading experts from NCCN’s 28 Member Institutions will present on new and emerging therapies, keys to optimization and implementation of treatment, and best practices in delivering oncology care across the continuum. “Cancer care has evolved dramatically since NCCN was founded 25…

Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Japan has initiated treatment in the global Phase 3 AGENT study.   Isofol’s drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC). The study is currently being conducted in the USA, Canada, Europe, Australia and now also in Japan. Isofol plans to start the trial in up to 15 clinics in Japan, in addition to the 80 clinics that are already open.   “A high pace is kept in our patient enrollment which enables the study’s…

While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation can have a contrary effect by promoting the survival of triple-negative breast cancer cells, according to research published online in the International Journal of Radiation Biology by Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute. Accounting for 15-20% of all breast cancers, triple-negative breast cancer is faster growing than other types of breast cancers. Dr. Sims-Mourtada’s latest study, “Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity…